Roth Capital Starts Acadia Pharmaceuticals (ACAD) at Buy
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $16.45 -0.84%
Rating Summary:
14 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 9
Rating Summary:
14 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 9
Join SI Premium – FREE
Roth Capital initiates coverage on Acadia Pharmaceuticals (NASDAQ: ACAD) with a Buy. PT $3.00.
For an analyst ratings summary and ratings history on Acadia Pharmaceuticals click here. For more ratings news on Acadia Pharmaceuticals click here.
Shares of Acadia Pharmaceuticals closed at $1.45 yesterday.
For an analyst ratings summary and ratings history on Acadia Pharmaceuticals click here. For more ratings news on Acadia Pharmaceuticals click here.
Shares of Acadia Pharmaceuticals closed at $1.45 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Acadia Pharma (ACAD) Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
- Victoria's Secret (VSCO) initiated with sell rating at Goldman Sachs on 'less attractive' risk/reward
- Northland Starts Bitfarms Ltd. (BITF) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
